NEW YORK (GenomeWeb) – Agilent Technologies announced Tuesday that the European Commission had granted expanded use in Europe for its Dako PD-L1 IHC 22C3 pharmDx, a companion diagnostic for Merck's Keytruda (pembrolizumab).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.